Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.
The transaction is expected to close in the second quarter of 2025, it added.
https://ca.finance.yahoo.com/news/sanofi-acquire-dren-bios-immunology-062906602.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.